Clinical Professor of Medicine, Tufts University School of Medicine
Hematology
Dr. Frederick R. Aronson, MD
|
|
Give Review
Frederick Aronson works in the field of Hematology. He studied medicine at Yale University School of Medicine. Yale University School of Medicine is a one of the best medicals schools. Yale University School of Medicine is ranked 7 in research and 57 in primary care medicine He has 9 awards "Regional Top Doctor", "CMS Meaningful Use Stage 1 Certification", "Team Science Recognition Award", "Co-Principal Investigator", "Fellow", "Principal Investigator", "Postdoctoral Research Fellowship", "National Research Service Award" and "Summer Research Award". Frederick Aronson is also published. He has 34 publications published. The lastest publication: "Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.' Dr. Frederick R. Aronson accepts all Medicare patients.
Publications
- Randomized trial of an allogeneic Melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous ...
- IL-2 rapidly induces natural killer Cell adhesion to human endothelial Cells. A potential mechanism for endothelial injury.
- Phase II trials of high-dose interleukin-2 and lymphokine-activated killer Cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other ...
- Phase II studies of recombinant human interleukin-4 in advanced renal Cancer and malignant melanoma.
- Nephrectomy for metastatic renal Cell carcinoma: a component of systemic treatment regimens.
- Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal Cell carcinoma: clinical and immu...
- Summary statistics and treatment decisions.
- Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell Cancer: five-year follow-up of the Cytokine Working Group Study.
- Interleukin-2-based therapy for metastatic renal cell Cancer: the Cytokine Working Group experience, 1989-1997.
- Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic Malignant melanoma.
- Kidney Cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trials.
- Kidney Cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines.
- Use of biological response modifiers for management of renal Cell carcinoma.
- A low rate of central Nervous system progression in a phase II trial of outpatient chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and interferon al...
- Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small Cell lung and head/neck carcinomas.
- A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer Cells for advanced renal Cell carcin...
- Phase II trial of high-dose interleukin-2 and lymphokine-activated killer Cells in Hodgkin's disease and non-Hodgkin's lymphoma.
- Gossypol effects on endothelial Cells and tumor blood flow.
- Pathogenesis of pulmonary edema during interleukin-2 therapy: correlation of chest radiographic and clinical findings in 54 patients.
- Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
- IL-4 inhibits IL-2 receptor expression and IL-2-dependent proliferation of human T Cells.
- Life-threatening bullous skin eruptions during interleukin-2 therapy.
- High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal Cell carcinoma.
- Interleukin-2 therapy in patients with metastatic Malignant melanoma: a phase II study.
- Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression...
- Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer Cells.
- Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer Cells in patients with metastatic or unresectable m...
- Insurance coverage for investigational therapy.
- Activated endothelial Cells resist lymphokine-activated killer Cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy.
- Recombinant human GM-CSF in myelosuppression of chemotherapy (continued)
- Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer Cells.
- Malignant granular lymphoproliferation after Epstein-Barr virus infection: partial immunologic reconstitution with interleukin-2.
- IL-2 stimulates the production of IL-1 alpha and IL-1 beta by human peripheral blood mononuclear Cells.
Schools
Yale University
Rhode Island Hospital
New England Med Center
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
- Team Science Recognition Award
- Co-Principal Investigator
- Fellow
- Principal Investigator
- Postdoctoral Research Fellowship
- National Research Service Award
- Summer Research Award
Education
-
Tufts Medical Center -
Brown University -
Yale University School of Medicine -
Johns Hopkins University
Drug Facts
| NPI NUMBER | 1417928334 | |
| NPPES Provider LastName | ARONSON | |
| NPPES Provider FirstName | FREDERICK | |
| NPPES Provider ZIPCode | 04074 | |
| NPPES Provider State | ME | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 490.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 54.0 | |
| Percent Opioid Claims | 11.02 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1417928334 |
| Last Name Of The Provider | ARONSON |
| First Name Of The Provider | FREDERICK |
| View All |
Similar Doctors
|
|
Dr. Helen F. Ryan, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew C. Dugan, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tracey F. Weisberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christian A. Thomas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew D. McKee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Devon L. Evans, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jacquelyn A. Hedlund, MD
This Doctor is OpenDoctor Recommended.
|